Noxopharm Limited 34 Note 8. Current assets - trade and other receivables Consolidated 2022 2021 $ $ Accounts receivable 5,584 4,400 GST receivable 201,893 277,816 R&D rebate receivable 5,002,616 5,500,000 Interest receivable 3,288 17,008 5,207,797 5,794,824 5,213,381 5,799,224 Other receivables are recognised at amortised cost, less any allowance for expected credit losses. Note 9. Current assets - other assets Consolidated 2022 2021 $ $ Prepayments 462,787 67,517 Inventories 1,146,492 311,510 1,609,279 379,027 The inventories are mainly materials that are used in the research and development process. These materials are recognised as an expense as and when they are utilised in the research and development process. The increase in prepayments is due to prepayments toward the next batch of inventory manufacture.
RkJQdWJsaXNoZXIy MjE2NDg3